04.04.23
Leonard A. Lauder and Ronald S. Lauder, along with the entire third generation of their family, William Lauder, Gary Lauder, Aerin Lauder Zinterhofer, and Jane Lauder, have committed $200 million to The Alzheimer's Drug Discovery Foundation (ADDF) to accelerate the discovery and development of drugs to prevent and treat Alzheimer's disease.
This is the largest gift ever given to the ADDF – underscoring the Lauder family's dedication to curing Alzheimer's.
The Lauder family's donation will fuel the ADDF to advance a new generation of drugs that are based on an understanding of the biology of aging that can be used in combination with anti-amyloid therapies to stop Alzheimer's in its tracks. This work is already well underway, with 75% of the clinical trials in today's robust and diverse drug pipeline aimed at novel targets.
ADDF's Chief Science Officer, Dr. Howard Fillit, says, "Many of the most promising treatments being studied right now are based on our understanding of the biology of aging, an approach long supported by the ADDF, which focuses on the many processes that go wrong in the aging brain to cause Alzheimer's. We believe we will conquer this disease using precision medicine approaches that have been successful in preventing and treating other diseases of chronic aging, such as cancer. The biomarkers being developed by the ADDF's Diagnostics Accelerator will play a key role, allowing us to pinpoint the best drugs to target the specific causes of each patient's Alzheimer's."
The next step for the ADDF is to bring to market a new generation of drugs that are based on an understanding of the biology of aging that can be used in combination with anti-amyloid therapies to stop Alzheimer's in its tracks. The Lauder family's donation will help the ADDF advance this next generation of drugs more quickly by allowing the organization to explore the full potential of the current pipeline and move the most promising research forward.
"This extraordinary gift from the Lauder family will change the way the world ages," said Mark Roithmayr, CEO of the ADDF. "This disease cannot be solved in a vacuum, and the Lauder family understands no one goes through Alzheimer's alone. This gift enables the ADDF to continue convening the world's best and brightest minds to solve this disease while reinvesting every penny back into the science and innovating the drug pipeline."
The gift comes at a critical time for the over six million Americans and their families currently living with Alzheimer's.
This is the largest gift ever given to the ADDF – underscoring the Lauder family's dedication to curing Alzheimer's.
Advancing New Alzheimer’s Drugs
The Lauders founded the ADDF in honor of their mother, Mrs. Estée Lauder, 25 years ago. The family's new donation comes at a critical time when new breakthroughs have emerged with the approval of several anti-amyloid therapies, which are making clinical trials more accurate and efficient. The ADDF provided early funding for the Amyvid PET scan, which played a critical role in getting these drugs across the finish line by tracking their ability to clear amyloid.The Lauder family's donation will fuel the ADDF to advance a new generation of drugs that are based on an understanding of the biology of aging that can be used in combination with anti-amyloid therapies to stop Alzheimer's in its tracks. This work is already well underway, with 75% of the clinical trials in today's robust and diverse drug pipeline aimed at novel targets.
ADDF's Chief Science Officer, Dr. Howard Fillit, says, "Many of the most promising treatments being studied right now are based on our understanding of the biology of aging, an approach long supported by the ADDF, which focuses on the many processes that go wrong in the aging brain to cause Alzheimer's. We believe we will conquer this disease using precision medicine approaches that have been successful in preventing and treating other diseases of chronic aging, such as cancer. The biomarkers being developed by the ADDF's Diagnostics Accelerator will play a key role, allowing us to pinpoint the best drugs to target the specific causes of each patient's Alzheimer's."
The next step for the ADDF is to bring to market a new generation of drugs that are based on an understanding of the biology of aging that can be used in combination with anti-amyloid therapies to stop Alzheimer's in its tracks. The Lauder family's donation will help the ADDF advance this next generation of drugs more quickly by allowing the organization to explore the full potential of the current pipeline and move the most promising research forward.
"This extraordinary gift from the Lauder family will change the way the world ages," said Mark Roithmayr, CEO of the ADDF. "This disease cannot be solved in a vacuum, and the Lauder family understands no one goes through Alzheimer's alone. This gift enables the ADDF to continue convening the world's best and brightest minds to solve this disease while reinvesting every penny back into the science and innovating the drug pipeline."
The gift comes at a critical time for the over six million Americans and their families currently living with Alzheimer's.
